XTL Biopharmaceuticals Announces Financial Results for the Year Ended Decembe...( VALLEY COTTAGE N.Y. March 20 /- X...),Health
Navigation Links
XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
Date:3/20/2008
VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL), a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatitis C, today announced its financial results for the year ended December 31, 2007.
At December 31, 2007, the Company had cash, cash equivalents and short- term bank deposits of $13.0 million, compared to $25.2 million at December 31, 2006. The decrease of $12.2 million during the year ended December 31, 2007 was attributable primarily to the Company's $7.5 million initial upfront license payment made in connection with the in-licensing of Bicifadine, a serotonin and norepinephrine reuptake inhibitor for the treatment of diabetic neuropathic pain, in January 2007, operating expenditures associated with the Phase 2b clinical trial of Bicifadine, the development of the DOS hepatitis C pre-clinical program, and operating expenditures associated with the Company's legacy hepatitis C clinical programs that were terminated in 2007, offset by $8.8 million in net proceeds from the private placement that was completed in November 2007.
The loss for the year ended December 31, 2007 was $24.9 million, or
$0.11 per ordinary share, compared to a loss of $15.1 million, or $0.08 per
ordinary share, for the year ended December 31, 2006, representing an
increase in net loss of $9.8 million. The increased loss was primarily
attributable to the $7.5 million upfront license fee in connection with the
in-licensing of Bicifadine and additional costs associated with the
Bicifadine clinical program, offset by lower costs associated with the
Company's legacy hepatit
'/>"/>
| SOURCE XTL Biopharmaceuticals Ltd. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
2. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Perrigo Company Announces Launch of Clobetasol Propionate Foam
6. Batesville Holdings Announces New Board of Directors in Preparation for March 31 Spin-Off from Hillenbrand Industries
7. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
8. Lifeway Foods Announces Expanded Distribution and Growing Success of ProBugs(TM) Organic Kefir for Kids
9. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
10. Blue Cross and Blue Shield of Illinois Announces Wellness Tools and Resources
11. Blue Cross and Blue Shield of Illinois Announces Campaign to Address Childhood Obesity
Post Your Comments:
(Date:11/25/2009)...SCO,Nov.25/PRNewswire/--TheBayAreaAirQualityManage...are the Air Alert forThursday,November2...nyothersolidfuel,bothindoorsandoutdoors. ,, "Co...tomorrow,"saidJackBroadbent,executiveofficeroftheA...ehealthoftheirneighborsandfellowcommunitymembersth...
(Date:11/25/2009)...discovery that grew out of a collaboration between...ffer hope to the nearly 10 million Americans who s...so known as hardening of the arteries, peripheral ...problem in which narrowed arteries reduce blood fl... flag for vascular disease, heart attack and strok...
(Date:11/25/2009)... Evaluation and treatment clinics to resum...tock (Vocus) November 25, 2009 -- Centegra Health ...and H1N1 vaccine shots at four Centegra Primary Ca...t of vaccine has arrived. The clinics are at CPC s...ry and will be open as follows: , Fr...
(Date:11/25/2009)...ov.25/PRNewswire/-- MISSIONSkincare ®isproudt...Jude.AspartofGNC,sannualSt.Jude ThanksandGiving ca...re,s new SUPER-C(TM)LipBalm willbedonatedtoSt.Ju...kea$1,$5or$10donationatcheckoutatoneoftheir5,000+r...1millionforSt.Judeduringtheir2009 ThanksandGiving ...
(Date:11/25/2009)...treat colorectal cancer also can reverse a rare st... therapy for the disease, researchers at Vanderbil...ntrier,s disease causes thickening of the stomach ..., as well as anemia and swelling in the feet and a...ed risk for gastric cancer. Previously, the only e...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2[0] Winter Spare the Air Alert in Effect for Thursday, November 26, 2009[0] Engineers, doctors at UCLA develop novel material that could help fight arterial disease[0] Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1[2] MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R)[1] Vanderbilt scientists report first effective medical therapy for rare stomach disorder
...Apollo hospital in Ahmedabad is to collaborate wit...ncer center (CBCC), to start a new radiation thera...CC of US is to supply new radiation therapy machin...hin the hospital premises a separate unit that wil...
...ers are more prone to losing their eyesight later ...
There are around 500,000 people in the UK with ... an estimated 54,000 people have the condition as ...MD Alliance UK, based on a survey of 1,023 British...
...ing modality has yet another discovery to its cred... called is a safe, non-surgical method of identify... accurate// and rapid way of diagnosing meningitis...erious brain infections such as abscesses and meni...
... report published by the Department of Veterans Af...control the cholesterol levels and provided a guid... not only bad for the heart and blood vessels, but...erol Education Month in USA, VA highlights screeni...
...Japanese Encephalitis epidemic continues to cause ...sed health officials are tight-lipped about the to...Pradesh government and yesterday admitted the drea...ical facilities in eastern Uttar Pradesh, where th...
...ents who come to the emergency room with cervical ...tected. In a study, which is published in the Ann... be useful to detect such injuries in patients ove...sible on regular x-rays. In fact, more than a thir...
Other Medicine News:Health News:High Cholesterol Can Be Controlled By Screening And Prevention 2Apollo Hospital to collaborate with US cancer center to open new radiation therapy department Smokers Face The Risk Of Becoming Blind In Later LifeMagnetic Resonance Spectrometry for speedy diagnosis of Brain disordersHigh Cholesterol Can Be Controlled By Screening And PreventionUttar Pradesh Encephalitis toll continues to rise - Over 600 deadCervical spinal injury patients may have more damage left undetected
(Date:11/25/2009)...MINGHAM,Mass.andSYDNEY,Nov.25/PRNewswire-FirstCall...IN),aleadinginnovatorandprovideroflessinvasive,min...zingthetreatmentofadvancedheartfailure,todayannoun...the21stAnnualPiperJaffrayHealthCareConferenceat8:0...ingheldattheNewYorkPalaceHotel,December1-2. ,, ...
(Date:11/24/2009)...HESDA,Md.,Nov.24/PRNewswire-Asia/--ChindexInternat...pendentAmericanproviderofWestern,healthcareproduct...ouncedthattheCompanywillattendthe21stAnnualPiperJa...mber1-2,2009,atthe,NewYorkPalaceHotel. , Mana...esday,December1,2009,andholdone-on-onemeetingsthr...
(Date:11/24/2009)...INE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix...reatmentsforaorticdisorders,announcedtodaythatitha...thepatentinfringementlawsuitbroughtagainstitinOcto...esDistrictCourtinIndianapolis,Indiana. ,, Endol...nitedStatesPatentandTrademarkOffice(USPTO)conducts...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2The Leapfrog Group Announces New Board Chair 50087 1The Leapfrog Group Announces New Board Chair 50087 2The Leapfrog Group Announces New Board Chair 50087 3Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 1Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 2Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 3Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 4Supply of Key Childrens Vaccine Almost Back to Normal 50081 1Supply of Key Childrens Vaccine Almost Back to Normal 50081 2Supply of Key Childrens Vaccine Almost Back to Normal 50081 3...NESS WIRE)--May 17, 2007 - Results,published this ...er,vaccine, GARDASIL (Quadrivalent Human Papilloma...as 100 percent effective in,preventing high-grade ...16 and 18, two types strongly associated with thes...d in women who were not,infected with HPV types ta...
...th International Symposium on,Myelodysplastic Synd...ew updated results,from a pivotal Phase II trial e...lood cancer known as myelodysplastic syndromes (MD... H. Lee Moffitt,Cancer Center & Research Insti...rrently taking place in Florence, Italy.,Breakthro...
Other Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |